Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Glucarpidase for Treatment of High-Dose Methotrexate Toxicity.
Gupta S, Kaunfer SA, Chen KL, Dias JA, Vijayan A, Rajasekaran A, Prosek J, Truong HL, Wood A, Bassil C, Renaghan AD, Shah CV, Zhang J, Glezerman I, Carlos C, Kelly K, Passero CJ, Drappatz J, Abudayyeh A, Shin D, Sperati CJ, Yelvington BJ, Kanduri SR, Neyra JA, Edmonston D, Shirali AC, Bansal A, Geara A, Mithani Z, Ziolkowski SL, Rashidi A, Jakubowski J, Pujari A, Bond DA, Dotson EK, Wall SA, Patton JT, Barreto JN, Hermann SM, Sheikh MS, Baz RC, Lee JH, Lucchesi N, Kolman M, Rasheed MA, Afzal A, Kang D, Mahesh A, Hsu R, Nicolaysen A, Tefera K, Schretlen C, Miller RM, Velez JCQ, Flannery AH, Aklilu AM, Anand S, Chandrasekhara S, Donley V, Patel A, Ni J, Krishnamurthy S, Ali R, Yilmam OA, Wells SL, Ortega JL, Green-Lingren OL, Leaf RK, Sise ME, Nayak L, LaCasce AS, Leung N, Leaf DE. Gupta S, et al. Among authors: lacasce as. Blood. 2025 Jan 6:blood.2024026211. doi: 10.1182/blood.2024026211. Online ahead of print. Blood. 2025. PMID: 39760780
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, Crombie JL, Kim AI, Weinstock M, Montegaard J, Walker HA, Greenman C, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Lo S, Olszewski AJ, Arnason JE, Ahn IE, Brown JR. Davids MS, et al. Among authors: lacasce as. J Clin Oncol. 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503. Online ahead of print. J Clin Oncol. 2024. PMID: 39645236
Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530].
Lurain K, El Zarif T, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, Chintapally N, Drolen CE, Feldman T, Haykal T, Nebhan CA, Kambhampati S, Li M, Mittra A, Lorentsen M, Kim C, Drakaki A, Morse M, Johnson DB, Mangla A, Dittus C, Ravi P, Baiocchi RA, Chiao EY, Rubinstein PG, Yellapragada SV, LaCasce AS, Sonpavde GP, Naqash AR, Herrera AF. Lurain K, et al. Among authors: lacasce as. Clin Lymphoma Myeloma Leuk. 2024 Dec;24(12):873. doi: 10.1016/j.clml.2024.10.011. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39603773 No abstract available.
A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.
Looka A, Qualls DA, Matthews D, Redd RA, Sakellis C, Duffy C, Dela Cruz J, Saucier A, Armand P, Crombie JL, Fisher DC, Jacobsen ED, Kim AI, LaCasce AS, Merryman RW, Parry EM, Jacobson CA. Looka A, et al. Among authors: lacasce as. Blood Adv. 2024 Nov 15:bloodadvances.2024012992. doi: 10.1182/bloodadvances.2024012992. Online ahead of print. Blood Adv. 2024. PMID: 39546746
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
Lurain K, Zarif TE, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, Chintapally N, Drolen CE, Feldman T, Haykal T, Nebhan CA, Thiruvengadam SK, Li M, Mittra A, Lorentsen M, Kim C, Drakaki A, Morse M, Johnson DB, Mangla A, Dittus C, Ravi P, Baiocchi RA, Chiao EY, Rubinstein PG, Yellapragada SV, LaCasce AS, Sonpavde GP, Naqash AR, Herrera AF. Lurain K, et al. Among authors: lacasce as. Clin Lymphoma Myeloma Leuk. 2024 Aug;24(8):523-530. doi: 10.1016/j.clml.2024.03.011. Epub 2024 Apr 5. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38714474
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.
Driessen J, de Wit F, Herrera AF, Zinzani PL, LaCasce AS, Cole PD, Moskowitz CH, García-Sanz R, Fuchs M, Müller H, Borchmann P, Santoro A, Schöder H, Zijlstra JM, Hutten BA, Moskowitz AJ, Kersten MJ. Driessen J, et al. Among authors: lacasce as. Blood Adv. 2024 Jun 11;8(11):2740-2752. doi: 10.1182/bloodadvances.2023012145. Blood Adv. 2024. PMID: 38502227 Free PMC article.
Frontline Treatment of Mantle Cell Lymphoma.
Ryan CE, Armand P, LaCasce AS. Ryan CE, et al. Among authors: lacasce as. Blood. 2024 Mar 18:blood.2023022352. doi: 10.1182/blood.2023022352. Online ahead of print. Blood. 2024. PMID: 38498174
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.
Nemec R, Scherrer-Crosbie M, Abramson JS, Redd R, Gilman HK, Ho T, Wu J, Heemelaar J, Neuberg D, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Friedman RS, LaCasce AS, Neilan TG, Soumerai JD. Nemec R, et al. Among authors: lacasce as. Leuk Lymphoma. 2024 Jun;65(6):783-788. doi: 10.1080/10428194.2024.2317343. Epub 2024 Feb 21. Leuk Lymphoma. 2024. PMID: 38380861 Clinical Trial.
148 results